DOCSLIB.ORG

ردﺎﺻﻣﻟا BNF 61-2011 a to Z Drugs Fact-2003

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ردﺎﺻﻣﻟا BNF 61-2011 a to Z Drugs Fact-2003 (A to Z drugs©2011) More than 1300 drugs المصادر: BNF 61-2011 A to Z drugs fact-2003 مﻻحظة : يحتوي هذا الجدول باﻻضافة لﻻدوية الى بعض اللقاحات والفيتامينات والمعادن يستخدم هذا الجدول فقط للتعرف على اسماء اﻻدوية واستخداماتها الطبية....ولمزيد من المعلومات راجع المصادر. Generic name Brand name & class& dosage form indications NO. Abacavir ZIAGEN{ Tablets, Oral solution} Treatment of HIV-1 in combination with other antiretroviral agents. 1. Class: Anti-infective, Antiviral ABATACEPT Orencia{ Intravenous infusion} It is licensed for moderate to severe active rheumatoid arthritis in combination with methotrexate, in patients unresponsive to other disease-modifying 2. Antirheumatic, Cytokine Modulators antirheumatic drugs (including methotrexate or a tumour necrosis factor (TNF) inhibitor); It is also licensed for the treatment of moderate to severe active pol articular juvenile idiopathic arthritis(in combination with methotrexate) in children who have not responded adequately to other disease- modifying antirheumatic drugs (including at least one tumour necrosis factor (TNF) inhibitor). Abciximab REOPRO{ Injection} Adjunct to percutaneous coronary intervention (PCI) to prevent ischemic complications in patients at high risk of abrupt closure of the treated vessel. 3. Intended for use with aspirin and heparin. Class: Antiplatelet aluminium oxide Brasivol{ Paste} acne vulgaris 4. ABRASIVE AGENTS acamprosate calcium CAMPRAL{ Tablet} maintenance of abstinence in alcohol dependence. 5. antialcoholic Acarbose PRECOSE, Glucobay{ Tablet} Patients with NIDDM who have failed dietary therapy. May be used alone or in combination with sulfonylureas. 6. Class: Antidiabetic Acebutolol SECTRAL{ Capsules, Tablets} Management of hypertension and premature ventricular contractions. 7. Class: Beta-adrenergic blocker ACECLOFENAC Preservex {Tablets} pain and inflammation in rheumatoid arthritis, osteoarthritis and ankylosing spondylitis 8. NSAIDs ACEMETACIN Emflex{ Capsules} pain and inflammation in rheumatic disease and other musculoskeletal disorders; postoperative analgesia 9. (Glycolic acid ester of indomethacin) NSAIDs Acenocoumarol Sinthrome(Tablets) prophylaxis of embolisation in rheumatic heart disease and atrial fibrillation; prophylaxis after insertion of prosthetic heart valve; prophylaxis and 10. (Nicoumalone) anticoagulant treatment of venous thrombosis and pulmonary embolism; transient ischaemic attacks Acetaminophen (Paracetamol) PANADOL{ Tablets} Relief of mild-to-moderate pain; treatment of fever. 11. Other { caplets, Oral suspension, Suppositories, Intravenous infusion} Class: Analgesic/antipyretic Acetazolamide DIAMOX{ Tablets} epilepsies (eg, petit mal, generalized seizures), (openangle) glaucoma and (closed-angle) glaucoma, prevention or lessening of symptoms associated 12. with acute mountain sickness, treatment of edema caused by CHF Class: Anticonvulsant/carbonic anhydrase inhibitor Acetohexamide Dymelor{ Tablets} Adjunctive therapy, used with dietary modification, in patients with noninsulin-dependent diabetes mellitus (type II) for lowering blood glucose level. 13. Class: Antidiabetic/sulfonylurea acetylcholine chloride MIOCHOL-E{ Intra-ocular irrigation, powder for reconstitution} cataract surgery, penetrating keratoplasty, iridectomy, and other anterior segment surgery requiring rapid complete miosis. 14. Cholernergic agonist (direct acting) , Ocular peri-operative drugs Acetylcysteine Parvolex{ Injection} Reduction of viscosity of bronchopulmonary mucous secretions in patients with chronic or acute lung diseases, pulmonary complications associated 15. Class: Respiratory inhalant/mucolytic, with cystic fibrosis, surgery, anesthesia, atelectasis caused by mucous obstruction; diagnostic bronchial studies; prevention or lessening of liver damage antidote after potentially toxic quantity of acetaminophen. Orphan drug status: IV form for acetaminophen overdose. Acetylsalicylic acid Aspirin,Empirin{ Tablets, Dispersible tablets, Suppositories, powder } Treatment of mild-to-moderate pain; fever; various inflammatory conditions; reduction of risk of death or MI in patients with previous infarction or 16. (ASA) Class: Analgesic/salicylate unstable angina pectoris or recurrent transient ischemia attacks or stroke in men who have had transient brain ischemia caused by platelet emboli. acipimox Olbetam{ Capsules} hyperlipidaemias of types IIb and IV in patients who have not responded adequately to diet and other appropriate measures. 17. Nicotinic acid group, Lipid-regulating drugs ACITRETIN Neotigason[Capsules] severe extensive psoriasis resistant to other forms of therapy; palmoplantar pustular psoriasis; severe congenital ichthyosis; severe Darier’s disease 18. Oral retinoids for psoriasis (keratosis follicularis) Acyclovir ZOVIRAX{ Tablets, Suspension, Intravenous infusion} treat infections caused by herpes viruses( genital herpes, cold sores shingles, and chickenpox.) 19. Class: Anti-infective, Antiviral adalimumab Humira { Injection} treatment of psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis, Crohn’s disease, 20. Cytokine modulators Adapalene Differin { Cream, Gel} Topical treatment of acne vulgaris. 21. Class: Retinoid Adefovir HEPSERA [Tablets] Treatment of chronic hepatitis B in adults with evidence of active viral replication and evidence of persistent elevations in serum aminotransferases 22. (ALT or AST) or histologically active disease. Anti-infective, Antiviral Adenosine Adenocard, Adenoscan { Intravenous infusion& Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with Wolff-Parkinson-White syndrome 23. Injection} Class: Antiarrhythmic AGALSIDASE ALFA and BETA Fabrazyme, Replagal [Intravenous infusion] Fabry’s disease (specialist use only) 24. Albendazole ALBENZA,ZENTEL Treatment of ascaris lumbricoides (round worm),trichuris trichiura (whipworm), ancylostoma duodenale,taenia(tapeworm). 25. Class: Antihelmintic Albumin Human Albunex, Albutein… Symptomatic relief and supportive treatment in management of shock, burns, hypoprothrombinemia, adult respiratory distress syndrome, cardiopul- 26. (Normal Serum Albumin) Class: Plasma protein fraction monary bypass, acute liver failure, acute nephrosis, sequestration of protein-rich fluids, erythrocyte resuspension, hypotension or shock during renal dialysis, hyperbilirubinemia and erythroblastosis fetalis. Albuterol Proventil, Ventolin { Syrup, Injection, Solution for intravenous infusion ,Inhalation},. Prevention and treatment of reversible bronchospasm associated with asthma and other obstructive pulmonary diseases. Adjunctive treatment of 27. (Salbutamol) Class: Bronchodilator, Sympathomimetic hyperkalemia in patients undergoing dialysis. ALCLOMETASONE DIPROPIONATE Modrasone [Cream, Ointment] inflammatory skin disorders such as eczemas 28. Topical corticosteroids Aldesleukin Proleukin [Injection] Metastatic Renal Cell Carcinoma, Metastatic Melanoma. 29. Class: Biologic response modifier Colorectal cancer, non-Hodgkin's lymphoma, after autologous bone marrow transplantation (ABMT). ALEMTUZUMAB MabCampath [Concentrate for intravenous infusion] is licensed for use in patients with chronic lymphocytic 30. immunomodulating drugs leukaemia for whom fludarabine treatment is not appropriate. Alendronate FOSAMAX{Tablets} Treatment of osteoporosis in postmenopausal women; prevention of osteoporosis in postmenopausal women at risk of developing osteoporosis; 31. Class: Hormone/Bisphosphonates treatment of osteoporosis in men; treatment of glucocorticoid-induced osteoporosis in men and women; treatment of Paget disease of the bone. ALENDRONIC ACID Fosamax (as sodium alendronate) {Tablets} .Treatment of postmenopausal osteoporosis, 10 mg 32. Bisphosphonates dailyor70 mg once weekly .Treatment of osteoporosis in men, 10 mg daily .Prevention and treatment of corticosteroid-induced osteoporosis in postmenopausal women not receiving hormone replacement therapy, 10 mg daily Alfa Methyldopa ALDOMET{Tablets} Treatment of HTN 33. Class: Antihypertensive, Antiadrenergic, centrally acting ALFACALCIDOL One-Alpha{ Capsules, Oral drops, Injection} vitamin D deficiency, also licensed for the management of postmenopausal osteoporosis. 34. (1a-Hydroxycholecalciferol) Vitamin D Alfentanil ALFENTA, Rapifen[Injection] Induction of analgesia and anesthesia in specific situations, monitored anesthesia care (MAC). 35. Class: Narcotic agonist analgesic Alfuzosin hydrochloride UROXATRAL, Xatral [Tablets] Relax smooth muscle in benign prostatic hyperplasia producing an increase in urinary flow-rate and an improvement in obstructive symptoms. 36. Alfa1-blocker ALGLUCOSIDASE ALFA Myozyme [Intravenous infusion] (specialist use only) Pompe disease 37. alimemazine tartrate Vallergan [Tablets, Syrup] urticaria and pruritus, premedication. 38. (Trimeprazine tartrate) Sedating antihistamines aliskiren Rasilez[Tablets] essential hypertension. 39. Renin inhibitors Alitretinoin Panretin, Toctino [Capsules] Treatment of cutaneous lesions in patients with AIDS-related KS. 40. Class:endogenous retinoid Allopurinol ZYLOPRIM, Zyloric[Tablets] Tablets: Treatment of primary or secondary gout, hyperuricemia resulting from chemotherapy for malignancies, recurrent calcium oxalate renal calculi. 41. Class: Tablets and injections: Management of patients with leukemia, lymphoma, and solid tumor malignancies when concurrently receiving cancer therapy Analgesic/gout/cytoprotective that causes elevations of serum and urinary
Load more

Recommended publications
  • Product & Price# of Barcodes
    Product & Price# of Barcodes <span class="hilite">Cleaning</span> Air Wick Freshmatic Ultra1 Starter Kit (2 gadgets + 2 refills) - $12.99 Air Wick Freshmatic Ultra4 Refill (4 pack/6.17 oz) - $13.99 Air Wick Scented Oils1 (1 warmer + 7 refills) - $11.99 Air Wick Scented Oils1 Refill (8 pack) - $12.99 Air Wick Candles (twin2 pack) - $9.99 Clorox Foaming Bathroom3 Cleaner (3 pack/30 oz) - $8.49 Clorox Toilet Wand (361 ct refill with bonus wand) - $16.49 Clorox Automatic Toilet1 Bowl Cleaner (6 ct/3.5 oz) - $10.79 Clorox Disinfecting Wipes1 (5 pack/78 ct) - $14.99 Clorox Green Works Natural2 Cleaner (twin pack) - $4.99 Clorox Oxi Magic (7.81 lbs) - $9.99 Clorox Clean Up (1802 oz + 32 oz trigger) - $10.49 Clorox Pool & Spa Shock1 Plus, 12 pk./1 lb. $34.99 Clorox Pool & Spa Algaecide and Clarifier, 2 pk./1 gal. $14.99 Clorox Pump 'n Clean (2 pumps + 2 refills/18 oz) - $9.99 Clorox Bleach (2/182 2oz bottles) - $5.99 Damp Rid Moisture 46 Pack Hanging - $9.99 DampRid Buckets (6 pack)1 - $9.99 Fabuloso All Purpose 3Cleaner (169 oz) - $7.99 Febreze Air Effects (32 pack/9.7 oz) - $6.99 Febreze Air Effects Heavy1 Duty Crisp Clean Air Freshener (twin pack/19.4 oz) - $5.99 Febreze Set and Refresh2 (2 ct) - $7.99 Febreze Fabric 2 ct. 541 oz. - $7.99 Febreze Car Vent Clips3 (4 ct) $8.99 Febreze Unstopables2 (3 pack/8.8 oz) 8.99 Formula 409 (180 oz 1+ 32 oz) - $11.99 Glade PlugIns (2 warmers1 + 6 refills) - $11.49 Glade PlugIns (8 pack2 refill) - $12.99 Kaboom (twin pack/403 oz) - $8.79 Liquid Plumbr Foam Pipesnake2 (3 pack/17 oz) - $8.99 Liquid Plumbr ProStrength3 (twin pack/80 oz) - $9.99 Lysol Neutra Air (3 pack/164 oz) - $9.99 Lysol Neutra Air Sanitizing4 Spray, 3 pk./16 oz.
    [Show full text]
  • Presentación De Powerpoint
    A FAVORABLE DECREASE IN THROMBOCYTE LEVELS CAUSED BY LMWH TREATMENT FOR A DVT PATIENT WITH REFRACTER ESSENTIAL THROMBOCYTOSIS:A case report Hakan Keski, MD, Hematology University of Health Sciences Ümraniye Educaon and Research Hospital, Clinic of Hematology Introducon: Low molecular weightheparins have been found at least as eecve as unfraconed heparin in proximal venous thrombosis and have been shown to further inhibit the in vivo thrombin generaon. Because of the various reasons, there may be some changes among the LMWHs regarding the paent’sclinical follow-ups. Case report: A 53-year-old male paent, paent weight: 88 kg For the paent JAK2 V617F posive essenal thrombocytosis (ET) was diagnosed in Haydarpaa Numune Educaon and Research Hospital in 2006. Paent has been followed in Ümraniye Educaon and Research Hospital the hematology clinic since May 2016. Medical Story (anamnesis): One month nadroparin calcium 3800 IU treatment was given to paent due to lower extremity deep vein thrombosis (DVT) in June 2008.The paent had DVT for the second me in the lower extremity in September 2013, this me enoxaparin sodium 6000 IU was given as treatment. Physical examinaon: Splenomegaly was conrmed with palpaon for 2 cm (168 mm measured with USG) Laboratory: At the me of diagnosis, WBC 10880, Hgb: 15,9 g/dl Hct % 46 Plt: 1820000, biochemical parameters such as urea, creanine, AST, ALT were normal. The paent inially received ASA 100 mg and hydroxyurea 500 mg 3x1 was also given and 3 months later, platelet value was 1750000, the paent has been accepted as refractor and anagrelide treatment has been added with the dossage 2x1, then 3x1 in addion to the current treatment.
    [Show full text]
  • 1Hol=C2 Light Water (C2 > C1) Patent Application Publication May 1, 2008 US 2008/O103092 A1 5 (1H2O=C2
    US 20080 103092A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0103092 A1 Pomytkin et al. (43) Pub. Date: May 1, 2008 (54) METHODS FOR INTRADERMAL, Publication Classification TRANSIDERMAL, ORTRANSMUCOSAL DELIVERY OF BIOLOGICALLY ACTIVE (51) Int. Cl. SUBSTANCES A6II 47/02 (2006.01) A6II 38/02 (2006.01) (76) Inventors: Igor Anatolievich Pomytkin, Moscow A6IR 48/00 (2006.01) (RU); Sergey Pavlovich Soloviev, (52) U.S. Cl. .................................... 514/8: 514/2: 514/769 Moscow (RU) (57) ABSTRACT Correspondence Address: NOTARO AND MICHALOS This invention relates to method for intradermal, transdermal 1OO DUTCH HILL ROAD or transmucosal delivering a biologically active Substance to a mammal in need thereof, which method comprises a step of SUTE 110 co-administering to said mammal with the biologically active ORANGEBURG, NY 10962-2100 (US) Substance an effective amount of an absorption enhancer, which is water comprising from about 99.760 to about 10 (21) Appl. No.: 11/817,919 99.999% of light isotopologue H, 0 and up to 100% of residual isotopologues H, '70, H., '80, HH'0, HH'70, (22) PCT Filed: Mar. 11, 2005 'HH'0, H, O, H, '70, and H 0. Such biologically (86) PCT NO.: PCT/RUOS/OO108 active substance is selected from the group consisting of drugs, physiologically active peptides, physiologically active S371(c)(1), proteins, glycoproteins, nucleic acid, nutrients, vitamins, and (2), (4) Date: Nov. 15, 2007 minerals. 5 1Hol=C2 Light Water (C2 > C1) Patent Application Publication May 1, 2008 US 2008/O103092 A1 5 (1H2O=C2 Light Water (C2 > C1) Licuid US 2008/O 103092 A1 May 1, 2008 METHODS FOR INTRADERMAL, TRANSDERMAL wherein the level of light water isotopologue 'H'Ois about ORTRANSMUCOSAL DELIVERY OF 99.7317% (Vienna Standard Mean Ocean Water, VSMOW), BIOLOGICALLY ACTIVE SUBSTANCES and wherein total level of all eight heavy isotopologues com prising at least one heavy isotopes H, O, and 'O is about TECHNICAL FIELD 0.2683% (e.g.
    [Show full text]
  • Antihypotensive Agent Disrupts the Immune System in Sepsis 12 June 2020
    Antihypotensive agent disrupts the immune system in sepsis 12 June 2020 Patients who go into septic shock are treated with with endotoxin, a bacterial cell-wall component. If the antihypotensive agent norepinephrine. mice were administered norepinephrine, their Researchers from Radboud University Medical immune response was strongly suppressed." Center published results in today's American Journal of Respiratory and Critical Care Medicine Furthermore, in mice with an actual bacterial revealing that its use is not without drawbacks: The infection, infusion of norepinephrine led to drug disrupts the immune system and increases increased bacterial growth in the spleen, liver, and susceptibility to infections. This may have negative blood, again indicating a weakened immune consequences for patients. Research into system. "We also studied the effect of vasopressin, alternatives is therefore justified. an alternative antihypotensive agent, on white blood cells and mice," Stolk says. "Interestingly, in Sepsis is a life-threatening inflammatory response contrast to norepinephrine, this drug has no effects spreading throughout the body due to an infection. on the immune system or defense against One in four patients with sepsis succumbs to it, infections." and it is the No. 1 cause of death around the globe. As such, sepsis was recently designated as Healthy volunteers a global health priority by the World Health Organization (WHO). Patients with sepsis have a "Next, we wanted to know whether the effects of severely dysregulated immune system, which norepinephrine also apply to humans," said Matthijs impairs clearance of the infection and leaves the Kox, head of the study. "We infused either body susceptible to new infections with an norepinephrine, vasopressin, or a placebo in three increased risk of death.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • +1-516-204-7793 Product Catalog
    MVP TRADING CO., INC. PRODUCT CATALOG - 2015 TEL: +1-516-204-7793 UNITS CATEGORY UNIT UPC DESCRIPTION PER CASE ACNE AIDS 724742007614 ALBA ACNE FACE/BDY WASH 8 OZ 6 ACNE AIDS 724742007638 ALBA DEEP CLEAN ACNE WASH 6 OZ 6 ACNE AIDS 724742007607 ALBA PORE ACNE WASH 6 OZ 6 ACNE AIDS 654749453872 AVALON BALANCING TONER 8.5 OZ 6 ACNE AIDS 724742003623 AVALON HONEY MANGO GEL 12OZ 12 ACNE AIDS 839977008012 CLEARASIL .65OZ ADULT CARE CRM 24 ACNE AIDS 839977005356 CLEARASIL 6.5OZ HYDRA O/F SENS 12 ACNE AIDS 39977005343 CLEARASIL 6.5OZ HYDRA O/F WASH 12 ACNE AIDS 839977009200 CLEARASIL ULT D/P CLN PADS 90'S 6 ACNE AIDS 839977005325 CLEARASIL ULT RAP ACT GEL 6.78Z 6 ACNE AIDS 839977009095 CLEARASIL ULT VANISH CREAM 1 OZ 24 ACNE AIDS 839977005073 CLEARASIL ULT WSH/MASK 6.78 OZ 6 ACNE AIDS 839977009224 CLEARASIL ULTRA FACE WASH 6.78Z 12 ACNE AIDS 381370035664 CLN & CLR CLEAR TCH SHEETS 50CT 24 ACNE AIDS 381370033424 CLN & CLR DLY PORE CLNSER 5.5OZ 24 ACNE AIDS 381371020805 CLN & CLR MORN BRST FACE CLNS 8 24 ACNE AIDS 381371020829 CLN & CLR MORN BRST FC SCRB 5Z 24 ACNE AIDS 381371157648 CLN & CLR NT RLX DP CLN FACE 8Z 24 ACNE AIDS 381370033875 CLN & CLR SENS FACIAL CLNR 8 OZ 24 ACNE AIDS 381370039914 CLN & CLR.75OZ ADV ACNE TRTMNT 24 ACNE AIDS 70501116906 NEUT #1169 CLR-PORE OIL CNT 8OZ 24 ACNE AIDS 70501153666 NEUT #15366 OIL-FR ACNE WSH 6OZ 12 ACNE AIDS 70501020036 NEUT #2003 4.2Z RAZ/DEF D/SCRUB 12 ACNE AIDS 70501020135 NEUT #2013 MEN MD LOTION SPF20 12 ACNE AIDS 70501023549 NEUT #2354 ADV ACNE THERAPY SYS 12 ACNE AIDS 70501027004 NEUT #270 ALCOHOL-FR
    [Show full text]
  • Midodrine Hydrochloride Tablets, USP Rx Only
    MIDODRINE HCL- midodrine hydrochloride tablet Eon Labs, Inc. ---------- Midodrine Hydrochloride Tablets, USP Rx Only WARNING Because midodrine hydrochloride tablets can cause marked elevation of supine blood pressure, it should be used in patients whose lives are considerably impaired despite standard clinical care. The indication for use of midodrine hydrochloride tablets in the treatment of symptomatic orthostatic hypotension is based primarily on a change in a surrogate marker of effectiveness, an increase in systolic blood pressure measured one minute after standing, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine hydrochloride tablets, principally improved ability to carry out activities of daily living, have not been verified. DESCRIPTION Midodrine hydrochloride is a vasopressor/antihypotensive agent. Midodrine hydrochloride is an odorless, white, crystalline powder, soluble in water and sparingly soluble in methanol having a pKa of 7.8 (0.3% aqueous solution), a pH of 3.5 to 5.5 (5% aqueous solution) and a melting range of 200°C to 203°C. It is chemically described as: (1) Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2- hydroxyethyl]-monohydrochloride, (±)-; or (2) (±)-2-amino-N-(ß-hydroxy-2,5- dimethoxyphenethyl)acetamide monohydrochloride. Midodrine hydrochloride’s molecular formula is C12H18N2O4HCl, its molecular weight is 290.7 and its structural formula is: Each tablet for oral administration contains 2.5 mg, 5 mg or 10 mg of midodrine hydrochloride and the following inactive ingredients: pregelatinized starch (corn starch), microcrystalline cellulose, colloidal silicon dioxide, magnesium stearate. In addition, the 5 mg tablets contain FD&C yellow No.
    [Show full text]
  • General Catalog.Pdf
    ICM ID UPC Item Description Manufacturer MFG ID Min Retail 00105071 024291115229 Bamboo Stir Fry Set 3 Pc Navajo Manufacturing Co, Inc. 25805 2 $ 4.99 00105230 046354315407 Magnetic Numbers & Letters Ja-Ru, Inc. 1405 2 $ 2.99 00105256 046354732600 Glider Air Force Foam Jet 1/cd Ja-Ru, Inc. 2311 2 $ 2.99 00105277 047878650005 Cooler Can Holder U.S. Poly Enterprise, Inc. S650A-BK200 2 $ 2.99 00105283 714415016807 Neon Shot Glasses 12ct Evriholder Products, LLC. SGLSICM0672 2 $ 2.99 00106116 039052810138 TS Luggage Smart Tags 2ct Conair Corporation TS92NLT 3 $ 4.99 00106119 039052008993 TS Adapter Plug 4pc Insulated Plugs Conair Corporation M500ENR 1 $ 17.99 00106133 039052813603 TS Deluxe PVC Luggage Tags 2ct Conair Corporation TS02VB 3 $ 4.99 00183145 085455201578 Opener Beer Bottle/Can Tapper Chef Craft Corporation 20157-TKT 2 $ 2.99 00183699 085455210808 Cocktail Sword Spears Asst 30ct Chef Craft Corporation 21080-TKT 2 $ 1.99 00183913 815290025011 Sink Scents Assorted Liv-It! LLC 501 2 $ 2.99 00184879 871290005941 Foot File - Perfect Pair 1/cd Donnamax, Inc. 134148 2 $ 2.99 00185272 616513704351 Eye Care Essentials 4pc Kit Cala - Shin's Trading Co. 70-435B 2 $ 4.99 00185579 769898062278 Blending Wedge - Flower Shaped 6 ct Swissco LLC 6227 2 $ 4.99 00186171 769898070198 Pumice Sponge Swissco LLC 7019 2 $ 4.99 00186775 687969001394 Comb - Soft Touch Shower Comb Swissco LLC 50383 2 $ 4.99 00186858 085455205682 Opener Jar and Cap Rubber 2pk Chef Craft Corporation 20568-TKT 2 $ 1.99 00187062 705654017045 Doggie Clean Up Bags 20pk Pet King Inc PK1704 2 $ 1.69 00187070 763615802512 Combo Cutlery Clear Plastic 48ct King Zak, Inc.
    [Show full text]
  • Medication Guide for a Safe Recovery
    Medication Guide For A Safe Recovery A guide to maintaining sobriety while receiving treatment for other health problems. Revision 1.0 -April 2008 Table of Contents Introduction..................................................................................2 How to Use this Guide..................................................................3 Class A Drugs (Absolutely Avoid)................................................4 Class B Drugs................................................................................8 (With Addiction Medicine Specialist/Doctor Approval Only) Class C Drugs (Generally Safe to Take).....................................12 Alcohol-Free Products..................................................................16 Incidental Exposure Index...........................................................22 www.talbottcampus.com Introduction From the Talbott Recovery Campus Welcome to the Talbott Recovery Campus guide for a safe and sustained recovery. This document was developed through a collaborative effort between some of the best minds in addiction care today and will help you make wise decisions, ensuring that medications you may be prescribed and incidental exposure to alcohol do not threaten your hard won recovery. This guide is divided into three sections and is based on the drug classification system developed nearly 20 years ago by Dr. Paul Earley and recently expanded on by Bruce Merkin, M.D., Renee Enstrom, Nicholas Link and the staff at Glenbeigh hospital. Part one provides a way of categorizing medications
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub
    US 20110263526A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0263526 A1 SATYAM (43) Pub. Date: Oct. 27, 2011 (54) NITRICOXIDE RELEASING PRODRUGS OF CD7C 69/96 (2006.01) THERAPEUTICAGENTS C07C 319/22 (2006.01) CD7C 68/02 (2006.01) (75) Inventor: Apparao SATYAM, Mumbai (IN) A6IP 29/00 (2006.01) A6IP 9/00 (2006.01) (73) Assignee: PIRAMAL LIFE SCIENCES A6IP37/08 (2006.01) LIMITED, Mumbai (IN) A6IP35/00 (2006.01) A6IP 25/24 2006.O1 (21) Appl. No.: 13/092.245 A6IP 25/08 308: A6IP3L/04 2006.O1 (22) Filed: Apr. 22, 2011 A6IP3L/2 308: Related U.S. Application Data 39t. O 308: (60) Provisional application No. 61/327,175, filed on Apr. A6IP3/10 (2006.01) 23, 2010. A6IPL/04 (2006.01) A6IP39/06 (2006.01) Publication Classification A6IP3/02 (2006.01) (51) Int. Cl. A6IP 9/06 (2006.01) A 6LX 3L/7072 (2006.01) 39t. W 308: A6 IK3I/58 (2006.01) A6IP II/08 (2006.015 A6 IK3I/55 (2006.01) A63/62 (2006.015 A6 IK 3/495 (2006.01) A6 IK 3/4439 (2006.01) (52) U.S. Cl. ........... 514/50: 514/166; 514/172: 514/217; A6 IK 3L/455 (2006.01) 514/255.04: 514/338; 514/356; 514/412; A6 IK 3/403 (2006.01) 514/420; 514/423: 514/510,536/28.53:540/67; A6 IK 3/404 (2006.01) 540/591; 544/396; 546/273.7: 546/318: 548/452: A6 IK 3/40 (2006.01) 548/500: 548/537; 549/464; 558/275 A6 IK3I/265 (2006.01) C7H 9/06 (2006.01) (57) ABSTRACT CO7I 71/00 (2006.01) CO7D 22.3/26 (2006.01) The present invention relates to nitric oxide releasing pro C07D 295/14 (2006.01) drugs of known drugs or therapeutic agents which are repre CO7D 40/12 (2006.01) sented herein as compounds of formula (I) wherein the drugs CO7D 213/80 (2006.01) or therapeutic agents contain one or more functional groups C07D 209/52 (2006.01) independently selected from a carboxylic acid, an amino, a CO7D 209/26 (2006.01) hydroxyl and a sulfhydryl group.
    [Show full text]
  • Idiopathic Orthostatic Hypotension, Midodrine, and Anaesthesia
    499 Idiopathic orthostatic hypotension, mido- P.J. Osborne MD, L.W. Lee MD drine, and anaesthesia A patient with idiopathic orthostatic hypotension receiving Idiopathic orthostatic hypotension (IOH), which was first chronic oral midodrine therapy required amwsthesia for coro- described in 1925, ~ manifests as postural hypotension, nary arter3., bypass grafting. A perioperative infusioo of phenyl- syncope, fixed heart rate, defective sweating, nocturia ephrine was substituted ,/'or midodrine, an alpha-2 agonist, and impotence. Urinary or faecal incontinence or consti- enabling hypotension resulting from low systemic vascular pation may also occur. Inappropriate cardiovascular resistance to be controlled easily. Anticipated adrenergic reflexes2 predispose to haemodynamic instability. Treat- receptor denert,ation hypersensitivi O, was noted. The only ment is symptomatic, and includes head-up body tilt at significant perioperative problem was one episode of ~Tncope night, elastic stockings, 9 o~-fludroconisone and mido- from orthostatic hypotension during the reambulation period. drine 3 (Gutron | - Chemie Linz AG, Linz, Austria), an oral oL-adrenergic agonist in use in Europe, but an Un patient atteint d'hypolension or/hostatique idiopathique investigational drug in North America. The anaesthetic recevant un traitement oral chronique tl la midodrine a requis management of patients with autonomic dysfunction has I'anesthe;sie pour pontage aortocoronarien. Une perfusion been described, 4-9 but this is the first report of a patient pEriop~ratoire de phEnyl~phrine fut substitude ti la midodrine, with IOH receiving chronic midodrine therapy undergo- un agoniste alpha 2, a permis ~ I'hypotension r~sultant d'une ing cardiac surgery. r~sistance vasculaire syst~mique basse d'e;tre contr~l(e facile- ment.
    [Show full text]
  • View Annual Report
    Perrigo Annual Report 2012 Contents 3 Financial Highlights 12 Business Segment Review 22 Financial Reconciliation 4 Shareholder Letter 14 2012 in Review Insert 125 Years of Perrigo 10 Key Events 20 Shareholder Information Corporate Profile 2 From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, dietary supplements and active pharmaceutical ingredients (API). Perrigo is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market. The Company’s primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Perrigo Annual Report 2012 Financial Highlights Year Ended Financial Results – June 25, June 30, % Reported (GAAP) (1) 2011 (2) 2 012 (2) Change In millions, except shares Net Sales $ 2,755.0 $ 3,173.2 15 and per share amounts Operating Income $ 490.2 $ 569.2 16 Income from Continuing Operations $ 340.6 $ 393.0 15 Diluted Earnings Per Share from Continuing Operations $ 3.64 $ 4.18 15 Average Diluted Shares Outstanding (000s) 93,529 94,052 Year Ended Financial Results – June 25, June 30, % Adjusted (Non-GAAP) (1) 2011 (3) 2 012 (3) Change 3 In millions, except shares Net Sales $ 2,755.0 $ 3,173.2 15
    [Show full text]